Genmab A/S

GMAB ·Healthcare, Drug Manufacturers - General, Denmark

Net Cash Flow Breakdown

FY2025 FY2024 FY2023

Total Cash from Operations: $1.07B

Line Item	Value	% of Total
Capital Expenditures	$53.0M	4.9%
Other Investing	$132.0M	12.3%
Stock Repurchases	$81.0M	7.6%
Other Financing	$8.0M	0.7%
Net Cash Flow	$797.0M	74.4%